Proterris
Proterris is a clinical-stage biopharmaceutical company focused on therapeutic uses of carbon monoxide, including low-dose inhaled CO for delayed graft function in renal transplant recipients and carbon monoxide-releasing molecules for fibrotic and inflammatory conditions. The company pursues inhaled and small-molecule CO therapies across indications such as acute liver failure, non-alcoholic steatohepatitis, acute kidney injury, renal fibrosis, and idiopathic pulmonary fibrosis, aiming to address ischemia-reperfusion injury and inflammatory disorders. Headquartered in Boston, the company was founded in 2012.
Top Stages
1 past transactions
Alfama
Acquisition in 2017
Alfama is a pharmaceutical company that develops Carbon Monoxide-Releasing Molecules (CORMs) for therapy. The company has produced hundreds of CORMs and obtained exceptional results in various animal models of chronic and acute human diseases. CORMs have the potential to expand CO-based therapy to a wide range of high-value indications, can be administered orally or intravenously, and offer a very attractive therapeutic window and safety profile.
It is based in Boston, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.